SSY Group Limited(02005.HK): Methocarbamol Tablets Approved for Marketing; Phloroglucinol API Granted Registration
NewTimeSpace News: On July 2, 2026, SSY Group Limited(02005.HK) released a voluntary announcement, stating that the Group is the first domestic enterprise to secure NMPA manufacturing registration approval for Methocarbamol Tablets (0.5g). Classified as Category 3 chemical drug, this product is deemed to have passed the consistency evaluation. As a muscle relaxant, Methocarbamol Tablets are mainly indicated for conditions such as joint and muscle sprains, lumbar muscle strain, and sciatica.
On the same day, phloroglucinol developed by the Group was approved by the NMPA for registration as an API applicable to marketed finished pharmaceutical products. Phloroglucinol is primarily used for acute spasmodic pain caused by digestive and biliary dysfunctions, acute spasmodic ureteral, bladder and renal colic, as well as spasmodic pain in gynecology.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- REGENT PACIFIC(00575.HK): Deep Longevity Blood Biological Age Model Proven to Predict Mortality and Hospitalisation Risks in Research
- SAM WOO CONS(03822.HK): FY 25/26 Annual Report - Profit Attributable to Shareholders stood at HKD 56.92 million, YoY increase of 420.2%
- REGENT PACIFIC(00575.HK): Wholly-owned Subsidiary Deep Longevity Named Runner-up in Nestlé VITAL Smart Aging Global Challenge
- SSY Group (02005.HK): Trustee Acquires 1 Million Shares Under Restricted Share Incentive Scheme
